Amyotrophic Lateral Sclerosis
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Purpose of Study
The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Eligibility
Age:
10 +Sex:
FemaleAccepting Volunteers:
YES
Conditions:
Amyotrophic Lateral Sclerosis
Status:
RECRUITING
Phase:
Phase 3
Clinical Trials ID
NCT04768972
Read Detailed Summary:
Start Date / End Date:
06 2021 - 06 2026
Enrollment:
95